Peptide Purity, Identity, and Assay: Three Different Analytical Claims

When a peptide report presents purity, identity and an assay result, does each result answer the same analytical question? The interpretation under examination is whether a reported percentage can stand in for all three claims. Evaluating that interpretation starts with the purpose of the analytical procedure, rather than the prominence of the number.

The useful question is not simply whether a percentage looks reassuring. It is whether the procedure was validated for the claim being made.

The evidence level

The official ICH Q2(R2) guideline on analytical procedure validation provides the foundation for this discussion. It treats assay/potency, purity, impurities and identity as distinct analytical purposes. It also calls for validation appropriate to the procedure's intended purpose.

This is regulatory documentation, not an original peptide experiment. An in vitro, animal or human study model does not apply. The guideline establishes a framework for evaluating analytical procedures rather than experimental findings about a particular peptide sample.

That distinction determines how the source should be used. It supports questions about the relationship between a procedure and its intended claim. It is not a comparative study of peptide-testing methods or a measurement of a particular material.

Separate the purposes

The existing framework is purpose-specific validation. Under ICH Q2(R2), analytical procedures may serve different quantitative or qualitative purposes. Reading a peptide report through that framework means keeping the stated purposes separate before interpreting their results together.

Three questions help make that distinction explicit:

• Identity: What identity claim is the procedure intended to establish?
• Purity: What purity claim is the procedure intended to evaluate?
• Assay: What assay or potency claim is the procedure intended to measure?

These are questions for interpreting documentation, not definitions of particular testing techniques. Their value is that they prevent one label from silently replacing another.

For example, a result presented under a purity heading should first be assessed as a purity claim. Treating it as an identity or assay conclusion would require justification beyond the shared appearance of analytical terminology. This is an interpretation of the guideline's separation of purposes, not a finding from a peptide experiment.

CaliLean's discussion of reading identity, purity and amount as separate questions provides related educational context. The governing principle here remains the official guideline: validation should fit the intended analytical purpose.

Support and boundaries

ICH Q2(R2) directly supports separating these analytical categories. It also identifies validation characteristics that include accuracy and precision. Other listed characteristics are specificity, detection and quantitation limits, linearity and range.

The list does not replace the intended-purpose question. A report can mention validation terminology without making clear which analytical claim that terminology supports. The appropriate reading is to connect the stated purpose with the validation evidence, rather than treating the presence of technical terms as a complete answer.

The regulatory framework alone does not establish a peptide sample's identity, purity or assay value. Those are conclusions about the tested material and require supporting analytical records. The guideline's categories provide a way to examine those records, not a substitute for them.

A further boundary concerns analytical conditions. The distinction between purposes does not demonstrate how changing chromatographic conditions changes a reported peptide purity estimate. That is a procedure-specific experimental question, so no numerical effect or direction of change follows from this regulatory framework.

The comparison therefore supports a narrower conclusion than the idea that one percentage answers every question. Distinct purposes require distinct justification. It does not establish which particular procedure performs best for a given peptide.

Read the claim

A practical reading framework can follow the same order as the regulatory logic: purpose first, validation evidence next, interpretation last. This is a documentation framework, not a laboratory protocol. It does not prescribe changes to analytical conditions.

Identify the purpose

Locate the report's stated analytical purpose before assessing its result. Is the claim about identity, purity, impurities or assay/potency? If the wording combines categories, keep those categories separate while reading the supporting documentation.

The central question is whether the result is being used for its stated purpose. A percentage without a clearly identified purpose leaves the reader deciding what the author meant. That is a problem of interpretation before it is a question about the numerical value.

Connect the validation

Look for the connection between the procedure's purpose and its validation evidence. ICH Q2(R2) identifies characteristics that can guide this assessment:

• Accuracy and precision.
• Specificity.
• Detection and quantitation limits.
• Linearity and range.

The purpose of naming these characteristics is not to create a universal checklist for every result. It is to ask which evidence supports the particular analytical claim. CaliLean's guide to assessing the scope of method-validation evidence offers a related way to organize that reading.

Keep conclusions bounded

Read the conclusion at the same level as the supporting record. An identity claim should not become a purity conclusion merely because both appear on the same document. Likewise, an assay claim needs justification appropriate to its own purpose.

A Certificate of Analysis applies only to the tested sample and the reported methods. It does not establish human safety or efficacy. This keeps interpretation within the scope of laboratory documentation rather than turning an analytical record into a consumer health claim.

The meaningful percentage

Within this framework, a meaningful percentage is one whose analytical purpose is clear and whose supporting validation can be inspected. That is an interpretive standard drawn from purpose-specific validation, not a universal threshold supplied by the guideline.

The same framework also makes uncertainty more precise. Instead of asking whether a report is generally convincing, ask which claim is supported and what conclusion is being attached to it. This separates a question about documentation from a question that needs experimental evidence.

A peptide report becomes easier to read when its claims remain distinct. The number may be the most visible part of the page. The analytical question gives it meaning.

How CaliLean helps

Deciding whether a peptide result answers its stated analytical question is where CaliLean's source-led education has a role. For researchers separating scientific evidence from peptide-market hype, CaliLean pairs research materials with evidence reviews and laboratory documentation, with a focus on distinguishing experimental evidence from consumer health claims.

Explore the Research Library

Sources

1. ICH Q2(R2) Validation of analytical procedures - Scientific guideline